Last updated: 2026-09-20 02:12:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Traws Pharma, Inc. (TRAW) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.48, with a market capitalization of $8.23M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.43 to $3.27. This page covers its latest market performance, valuation, price trends and company information.
$8.23M | |
$0.54 | |
$24.75 | |
$0.43 | |
$0.54 | |
173.13K | |
123.86K | |
-- | |
$3.27 | |
$0.43 | |
-- | |
-- |
Traws Pharma, Inc. (TRAW) last closed at $0.54 as of 2026-09-18 23:31:00, unchanged from the previous close of $0.54.
During the latest regular trading session, TRAW traded between $0.43 and $24.75, with a volume of 173.13K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Traws Pharma, Inc. (TRAW) moved from $0.53 to $0.48, representing a decline of 9.31% ($0.05).
The stock traded between $0.48 and $0.59 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 89.79 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.8%
TRAW is currently trading at $0.48, placing it 1.8% of the way from its 52-week low of $0.43 to its 52-week high of $3.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Traws Pharma, Inc. (TRAW) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.